Compare FNB & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FNB | PTCT |
|---|---|---|
| Founded | 1864 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5B | 6.1B |
| IPO Year | N/A | 2013 |
| Metric | FNB | PTCT |
|---|---|---|
| Price | $18.07 | $69.45 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 18 |
| Target Price | $19.10 | ★ $76.28 |
| AVG Volume (30 Days) | ★ 6.6M | 1.1M |
| Earning Date | 01-20-2026 | 02-19-2026 |
| Dividend Yield | ★ 2.66% | N/A |
| EPS Growth | ★ 22.84 | N/A |
| EPS | 1.56 | ★ 8.94 |
| Revenue | $1,679,096,000.00 | ★ $1,779,150,000.00 |
| Revenue This Year | $14.53 | $132.16 |
| Revenue Next Year | $7.90 | N/A |
| P/E Ratio | $11.58 | ★ $7.77 |
| Revenue Growth | 10.77 | ★ 97.54 |
| 52 Week Low | $10.88 | $35.95 |
| 52 Week High | $19.14 | $87.50 |
| Indicator | FNB | PTCT |
|---|---|---|
| Relative Strength Index (RSI) | 52.53 | 32.97 |
| Support Level | $17.21 | $69.75 |
| Resistance Level | $19.14 | $76.99 |
| Average True Range (ATR) | 0.45 | 2.68 |
| MACD | -0.01 | -0.53 |
| Stochastic Oscillator | 44.67 | 1.65 |
F N B Corp provides a full range of financial services, principally to consumers, corporations, governments and small- to medium-sized businesses. It has three reportable business segments: Community Banking, Wealth Management and Insurance. The majority of revenue is from the Community banking segment. It offers commercial & consumer banking services. Commercial banking solutions include corporate banking, small business banking, investment real estate financing, business credit, capital markets & lease financing. Consumer banking products & services include deposit products, mortgage lending, & consumer lending & a complete suite of mobile & online banking services.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.